Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Neurology, Neurosurgery, and Psychiatry|January 18, 2003
Deriving summary indices of health status from the Amyotrophic Lateral Sclerosis Assessment Questionnaires (ALSAQ-40 and ALSAQ-5)C Jenkinson, J M Norquist, R Fitzpatrick
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 25, 2012
Methods for interpreting change over time in patient-reported outcome measuresK W Wyrwich, J M Norquist, W R Lenderking, et al.
Journal of Internal Medicine|August 22, 2006
The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigationP Lips, D Hosking, K Lippuner, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 17, 2004
A comparison of Rasch with Likert scoring to discriminate between patients' evaluations of total hip replacement surgeryR Fitzpatrick, J M Norquist, C Jenkinson, et al.
International Journal of Clinical Practice|October 10, 2013
The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapyT Rhodes, J M Norquist, C McCrary Sisk, et al.
International Journal of Clinical Practice|April 16, 2008
Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trialJ F Paolini, Y B Mitchel, R Reyes, et al.
ESMO Open|August 9, 2021
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 studyE Van Cutsem, A Valderrama, Y-J Bang, et al.
ESMO Open|May 28, 2025
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinomaR S Finn, M Kudo, P Merle, et al.
Frontiers in Oncology|October 22, 2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinomaJ-P Machiels, Y Tao, L Licitra, et al.
Pageof 1